
via Genetic Engineering and Biotechnology News
LumosVar — a name inspired by Harry Potter — could help physicians provide genomic-based treatments for their patients
By conjuring the spell “Lumos!” wizards in the mythical world of Harry Potter could light up the tip of their magic wands and illuminate their surroundings. So, too, does LumosVar, a computer program developed by the Translational Genomics Research Institute (TGen), “light up” cancer-causing genetic Var-ients, or mutations, illuminating how physicians might best treat their patients.
A study published today in the scientific journal Frontiers in Oncology describes how researchers at TGen, an affiliate of City of Hope, developed LumosVar to create a tool that can accurately identify cancer-causing mutations from patient tumor samples.
In the case of archived samples from patients for which treatment outcome results are known, these represent a treasure trove of information that could accelerate research by investigators and physicians in predicting responses of future patients to particular treatments.
“There are many open questions in precision oncology that can only be answered by collecting large amounts of patient genomic data linked to treatment response and clinical outcomes,” said Dr. Rebecca Halperin, a Research Assistant Professor in TGen’s Quantitative Medicine and Systems Biology Program.
“The approach we outline in this study should enable researchers to use archival samples more effectively. Accurately calling, or identifying, somatic variants — those DNA changes specific to a patient’s cancer — are the first step in any analysis,” said Dr. Halperin, the study’s lead author.
However, archived tumor samples are frequently not accompanied by the patients’ normal — or germline — genetic information, making it difficult to distinguish the patient’s normal DNA variants to their mutated and cancerous DNA changes.
LumosVar is a precise enough tool that it not only can detect the cancerous DNA from a patient sample, but it also can differentiate the adjacent normal DNA that may surround the tumor in the sample. Comparing the patient’s normal DNA from a suspected cancer-causing mutation is critical to eliminating benign, non-cancerous variants in the sample — “false positives” — and ensuring that the tissue sample analysis is as accurate as possible.
A high level of accuracy is needed for physicians to use this information in precision medicine, determining what treatment each individual patient should receive.
“The sequencing of DNA from tissue adjacent to the tumor could help identify somatic, or cancer-causing, mutations when another source of normal tissue is not available,” said Dr. Sara Byron, Research Assistant Professor in TGen’s Integrated Cancer Genomics Division, and also the study’s senior author.
Learn more: AS IF BY MAGIC: TGEN DEVELOPS PROGRAM THAT LIGHTS UP CANCER-CAUSING MUTATIONS
The Latest on: Genomic-based treatments
via Google News
The Latest on: Genomic-based treatments
- Exact Sciences: Patching The Acquisitions Togetheron January 21, 2021 at 5:57 am
Exact Sciences is pursuing it by acquiring complementary companies. The technologies are interesting and promise to bear fruits in the future. Failure to achieve a mass-market multi-cancer test might ...
- Artificial Intelligence Can Predict Prostate Cancer Recurrenceon January 15, 2021 at 6:32 am
An artificial intelligence tool is able to examine data from MRI scans and predict the likelihood that prostate cancer will recur after surgical treatment.
- Artificial intelligence tool for reading MRI scans could transform prostate cancer surgery and treatmenton January 15, 2021 at 6:23 am
"Genomic-based tests cost several thousand dollars ... method for making both short-term and long-term decisions on treatment." Data generated from the AI algorithms can be used to address two ...
- Florida Cancer Specialists & Research Institute Welcomes Dr. Jessica Stineon January 12, 2021 at 11:11 pm
Florida Cancer Specialists & Research Institute (FCS) welcomes Board-certified gynecologic oncologist Jessica Stine, MD. She is caring for patients at the FCS New Port Richey location at 8763 River ...
- Florida Cancer Specialists & Research Institute Welcomes Dr. Jessica Stineon January 12, 2021 at 6:56 pm
and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our values are embodied by our outstanding team of highly trained and dedicated physicians ...
- Leading Statewide Oncology Practice Florida Cancer Specialists Appoints Executive Board Memberson January 4, 2021 at 6:30 am
and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our values are embodied by our outstanding team of highly trained and dedicated physicians ...
- Florida Cancer Specialists & Research Institute Expands Care With New Location in Delray Beachon December 11, 2020 at 6:35 pm
and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our values are embodied by our outstanding team of highly trained and dedicated physicians ...
- Providers' Behavioral beliefs regarding the Delivery of Genomic Medicine at the Veterans Health Administrationon December 1, 2020 at 4:00 pm
In the future, genome-based medicine will become the standard practice for prevention, treatment, and management of common chronic diseases. Genomic-based clinical applications will allow ...
- Intervenn Biosciences IDs COVID-19 risk biomarkers using glycoproteomicson October 13, 2020 at 4:00 pm
It also is looking at devising a test that could be used in the clinical setting to guide triage and treatment decisions ... “There is an overabundance of companies that are looking at genomic-based ...
- 2019 ASCO Annual Meeting Ion August 16, 2020 at 11:49 am
Hurvitz et al. Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new ...
via Bing News